Proteome blood test developer Seer emerges with $36M in funding

test tubes
Seer aims to use population-level proteomic analyses and machine learning to develop blood tests that can detect diseases before symptoms appear, debuting with series A and B rounds already completed. (Pixabay)

Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases.

Seer employs nanotechnology, protein chemistry and machine learning algorithms to profile the tens of thousands of data points gathered from the proteins found in an individual person’s sample, including unique findings and data on protein relationships. Its platform aims to capture this information from many patients simultaneously and analyze the data using artificial intelligence systems.

“While genomic data has represented a massive step forward in helping us understand and more precisely treat disease, it is has shown limited ability to detect early stage disease and track disease progression,” said Omid Farokhzad, Seer’s founder and CEO. “Proteomics reveals the relatively much larger body of data about health status and disease that could be used by clinicians.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The startup’s pipeline follows a multistep process: first, its Proteograph platform is used to profile a broad array of the body’s proteins. Then, Seer employs its machine learning algorithms to analyze the resulting volume of information and generate insights into the progression of diseases at the population level.

Finally, that data will be used to develop new blood tests aimed at detecting diseases before their symptoms appear.

Seer was founded by Farokhzad and Chief Business Officer and President Philip Ma, along with Robert Langer, an institute professor at MIT who chairs the company’s scientific advisory board.

Farokhzad previously helped start Selecta Biosciences, a former Fierce 15 winner and currently serves as its chairman. He previously founded Bind Therapeutics, which filed for bankruptcy in 2016 following disappointing phase 2 results for its nanoparticle cancer drug and was later sold to Pfizer for $40 million.

Ma joined after leaving Biogen, where he was VP for digital health technologies and data sciences, a group he helped establish at the company in 2015, and served as a senior partner at McKinsey & Company.

The company has also brought on Applied Proteomics’ Chief Scientific Officer John Blume to be its VP of research; Crescendo Biosciences’ Bill Manning to serve as product development VP; Pfizer’s VP of nanomedicine development and manufacturing, Greg Troiano, as its chief engineer; Crescendo CTO Lyndal Hesterberg as a distinguished fellow; and Oncocyte’s clinical and regulatory affairs VP, Lyssa Friedman, to head up its clinical operations.

Seer has already completed series A and B financing founds, raising $36 million with the help of Maverick Ventures and Invus, alongside other investors.

The funding will help advance its platform and build out the company’s database of proteins, as well as support its discovery and product development programs. Seer also hopes to collaborate with biopharmaceutical industry partners to develop new products using its Proteograph system.

“We were impressed not only by Seer’s novel technology platform and early data, but also by the team’s vision for the broad application of its proteomic data, especially for early disease detection when potentially lethal diseases may be cured,” said David Singer, managing partner of Maverick Ventures.

Suggested Articles

Bio-Rad Laboratories received FDA clearance for two digital PCR products designed to monitor CML patients’ molecular responses to treatment.

Neuspera Medical raised a total of $26 million through the second tranche of a series B round, to fund clinical testing programs for its implants.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.